2'-O-{3-[(3-furanylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A | 1236143-01-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2'-O-{3-[(3-furanylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
• 英文别名: N-[3-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyloxan-3-yl]oxypropyl]furan-3-carboxamide
• CAS: 1236143-01-3
• 化学式: C₄₆H₈₁N₃O₁₄
• 分子量: 900.161
• InChiKey: CRDDHEKHGRHXAF-GCFGWCMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  63
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  211
• 氢给体数：
  5
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  3-糠酸 、 2'-O-(3-aminopropyl)-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A 在 1-羟基苯并三唑 、 哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.45h， 生成 2'-O-{3-[(3-furanylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
  参考文献：
  名称：

  [EN] 9-DEOXO- 9A-METHYL- 9A- AZA- 9A-H0M0ERYTHR0MYCIN A DERIVATIVES FOR THE TREATMENT OF NEUTROPHIL DOMINATED INFLAMMATORY DISEASES
  [FR] DÉRIVÉS DE 9-DÉOXO-9A-MÉTHYL-9A-AZA-9A-HOMOÉRYTHROMYCINE A POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES DOMINÉES PAR LES NEUTROPHILES

  摘要：

  式(I)中的2'-0-取代的14-或15-成员氮杂环巨环内酮类化合物，其中R6代表(i)-C1-8烷基，未取代或在末端碳原子处被羟基、-C1-3烷氧基和-C(O)OC1-3烷基中的一种选择的基团取代，或者当-C1-8烷基是支链时，替代可以选择性地由两个末端碳原子的每个都带有一个羟基基团，(ii)-CH(NH2)C1-4烷基，其中-C1-4烷基基团可以选择性地被O、S和N中选择的杂原子中断，(iii)-CH2N(R7)(R8)，其中R7和R8各自独立地代表H或-C1-3烷基，前提是R7和R8不能同时代表H，(iv)含有最多2个O、S和N中选择的杂原子的4-6成员杂环，其中该杂环未取代或被-C1-3烷基取代，(v)5-6成员杂芳环，未取代或被一个到三个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代，(vi)-CH(NH2)CH2-芳基，其中芳基可以未取代或被一个或两个独立选择的-C1-3烷基、-C1-3烷氧基和羟基取代，(vii)-C3-7环烷基，或(viii)苯基未取代或被一个或两个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代，或其盐，用于治疗中性粒细胞主导的炎症性疾病，特别是用于治疗由中性粒细胞浸润引起的中性粒细胞主导的炎症性疾病和/或与中性粒细胞功能改变相关的疾病，以及它们的制备方法，作为治疗剂的使用以及其盐。

  公开号：

  WO2010086350A1

文献信息

• Compounds
  申请人：Alihodzic Sulejman

  公开号：US20110281812A1

  公开（公告）日：2011-11-17

  2′-O-substituted 14- or 15-membered azalide macrolides of Formula (I) wherein R 6 represents (i) —C 1-8 alkyl, unsubstituted or substituted at the terminal carbon atom by a group selected from hydroxy, —C 1-3 alkoxy and —C(O)OC 1-3 alkyl, or when —C 1-8 alkyl is branched, substitution can alternatively be by a hydroxyl group at each of two terminal carbon atoms, (ii) —CH(NH 2 )C 1-4 alkyl, wherein the —C 1-4 alkyl group may be optionally interrupted by a heteroatom selected from O, S and N, (iii) —CH 2 N(R 7 )(R 8 ), wherein R 7 and R 8 each independently represent H or —C 1-3 alkyl provided that R 7 and R 8 cannot both simultaneously represent H, (iv) a 4-6-membered heterocyclic ring containing up to 2 heteroatoms independently selected from O, S and N, wherein the heterocyclic ring is unsubstituted or substituted by —C 1-3 alkyl, (v) 5-6 membered heteroaromatic ring, unsubstituted or substituted by one to three groups independently selected from halo, hydroxyl, —C 1-3 alkyl, —C 1-3 alkoxy, —CF 3 , —OCF 3 and —NH 2 , (vi) —CH(NH 2 )CH 2 -aryl wherein the aryl group may be unsubstituted or substituted by one or two substituents independently selected from —C 1-3 alkyl, —C 1-3 alkoxy and hydroxyl, (vii) —C 3-7 cycloalkyl, or (viii) phenyl unsubstituted or substituted by one or two groups independently selected from halo, hydroxyl, —C 1-3 alkyl, —C 1-3 alkoxy, —CF 3 , —OCF 3 and —NH 2 , or salts thereof, useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to methods for their preparation, to their use as therapeutic agents, and to salts thereof.
• [EN] 9-DEOXO- 9A-METHYL- 9A- AZA- 9A-H0M0ERYTHR0MYCIN A DERIVATIVES FOR THE TREATMENT OF NEUTROPHIL DOMINATED INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE 9-DÉOXO-9A-MÉTHYL-9A-AZA-9A-HOMOÉRYTHROMYCINE A POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES DOMINÉES PAR LES NEUTROPHILES
  申请人：GLAXOSMITHKLINE ZAGREB

  公开号：WO2010086350A1

  公开（公告）日：2010-08-05

  2'-0-substituted 14- or 15-membered azalide macrolides of Formula (I) wherein R6 represents (i) -C1-8alkyl, unsubstituted or substituted at the terminal carbon atom by a group selected from hydroxy, -C1-3alkoxy and -C(O)OC1-3alkyl, or when -C1-8alkyl is branched, substitution can alternatively be by a hydroxyl group at each of two terminal carbon atoms, (ii) -CH(NH2)C1-4alkyl, wherein the -C1-4alkyl group may be optionally interrupted by a heteroatom selected from O, S and N, (iii) -CH2N(R7)(R8), wherein R7 and R8 each independently represent H or -C1-3alkyl provided that R7 and R8 cannot both simultaneously represent H, (iv) a 4-6-membered heterocyclic ring containing up to 2 heteroatoms independently selected from O, S and N, wherein the heterocyclic ring is unsubstituted or substituted by -C1-3alkyl, (v) 5-6 membered heteroaromatic ring, unsubstituted or substituted by one to three groups independently selected from halo, hydroxyl, -C1-3alkyl, -C1-3alkoxy, -CF3, -OCF3 and -NH2, (vi) -CH(NH2)CH2-aryl wherein the aryl group may be unsubstituted or substituted by one or two substituents independently selected from -C1-3alkyl, -C1-3alkoxy and hydroxyl, (vii) -C3-7cycloalkyl, or (viii) phenyl unsubstituted or substituted by one or two groups independently selected from halo, hydroxyl, -C1-3alkyl, -C1-3alkoxy, -CF3, -OCF3 and -NH2, or salts thereof, useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to methods for their preparation, to their use as therapeutic agents, and to salts thereof.

  式(I)中的2'-0-取代的14-或15-成员氮杂环巨环内酮类化合物，其中R6代表(i)-C1-8烷基，未取代或在末端碳原子处被羟基、-C1-3烷氧基和-C(O)OC1-3烷基中的一种选择的基团取代，或者当-C1-8烷基是支链时，替代可以选择性地由两个末端碳原子的每个都带有一个羟基基团，(ii)-CH(NH2)C1-4烷基，其中-C1-4烷基基团可以选择性地被O、S和N中选择的杂原子中断，(iii)-CH2N(R7)(R8)，其中R7和R8各自独立地代表H或-C1-3烷基，前提是R7和R8不能同时代表H，(iv)含有最多2个O、S和N中选择的杂原子的4-6成员杂环，其中该杂环未取代或被-C1-3烷基取代，(v)5-6成员杂芳环，未取代或被一个到三个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代，(vi)-CH(NH2)CH2-芳基，其中芳基可以未取代或被一个或两个独立选择的-C1-3烷基、-C1-3烷氧基和羟基取代，(vii)-C3-7环烷基，或(viii)苯基未取代或被一个或两个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代，或其盐，用于治疗中性粒细胞主导的炎症性疾病，特别是用于治疗由中性粒细胞浸润引起的中性粒细胞主导的炎症性疾病和/或与中性粒细胞功能改变相关的疾病，以及它们的制备方法，作为治疗剂的使用以及其盐。